IMS LifeCycle – R&D Focus Patent Focus and New Product Focus Product developments since 2004

IMS LifeCycle R&D Focus Data Enhancements Searching on the new Mode of Administration field with following options: –injection (including intravenous, intra-muscular, subcutaneous injections) –inhalation –intranasal –implant –lingual –oral –per rectum –stent –topical –sublingual –vaginal

IMS LifeCycle R&D Focus Context Paragraphs Development Summary Commercial Overview, R&D Update, Regulatory Progress, Licensing Partnering, Analyst Predictions Scientific Summary Preclinical Data, Clinical Data further subdivided by disease.

IMS LifeCycle R&D Focus New Mechanism of Action Terms Over 30 new action terms added including: Fixed-combination Vanilloid receptor agonist, Vanilloid receptor antagonist, SV2A ligand, Vascular targeting agent, Vascular adhesion protein 1 inhibitor, Syk tyrosine kinase inhibitor, Ghrelin agonist, Ghrelin antagonist, Immunoconjugate, Ubiquitin ligase inhibitor, CFTR inhibitor, Kainate antagonist

IMS LifeCycle R&D Focus New Indications Over 50 new indications added including: Pouchitis, Bronchiectasis, Botulism, Vaginal atrophy, Behcet disease, Edema, Macular edema, Mouth ulcer, Mycobacterial infection, Uveitis, HIV-related lipodystrophy, Gastritis, FSAD (female sexual arousal disorder), Stutter

IMS LifeCycle R&D Focus New Phases Discovery - covers drug discovery programs - both collaborations between companies and internal drug discovery programs - where no real lead compound has yet been identified and has begun preclinical evaluation, and including programs based on a target or gene Technology - used for all drug design technologies (including libraries and screening technologies) and delivery systems In addition to Preclinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Marketed, Suspended, Discontinued and Withdrawn

IMS LifeCycle R&D Focus Anatomical Therapy Classes (ATC) Profiles* A total of 123 ATC profiles ( yr end 2004) have been carefully selected by our editorial team on the following basis: –they are within the top 100 leading ATCs –they are within the top 25 fastest growing ATCs –they have at least 20 active significant drugs in active development –they feature important new fixed combination drugs (i.e. J7B, R3E, R3F)

IMS LifeCycle R&D Focus Expanded Patent coverage Now covering patents on fixed combinations and drugs in delivery systems – since 2004 Improved History record now including patentee in product patent application

IMS LifeCycle Patent Focus Expanded Patent coverage Now covering patents on fixed combinations and drugs in delivery systems Recalculated all Italian Old Law Supplementary Protection Certificates (CCPs) Added and monitoring SPCs for 10 New EU member states in addition to other 15 original EU countries and Switzerland – from 1 May 2004

IMS LifeCycle Patent Focus Expanded Patent coverage Including product description of drug delivery systems to aid understanding of DDS claims Increased coverage of Orange Book and Canadian Register entries Coverage of patent extensions USA, Japan, Australia

IMS LifeCycle New Product Focus Increased number of new products added year on year

Knowledge Link 2004 Integrated Service R&D Pipeline Pharmaceutical Company Pharmaceutical Sales Data

Knowledge Link Integrated Service new since 2004 Patents Information Increased Sales Data coverage Country Market Forecasts Reuters Pharmaceutical News

IMS LifeCycle Patent Focus new during 2006 Review of new EU members states patents Improved Japanese patent information and patent extensions

Knowledge Link Integrated Service - new at end 2006 Product Launch Service

Chemical Pioneer 2004 What is it? All R&D Focus attributes with Chemical Synthetic Paths - Substructure searching - Key intermediates - Reaction steps - Literature references - Mainly R&D Drugs preclinical – Marketed (NCEs)

Chemical Pioneer developments since 2004 Reaction conditions – catalysts, reagents, physical conditions Named Reactions Claimed Intermediates Process Patent reaction schemes for drugs losing protection in next 10 years Companies patenting processes for claimed intermediates